Nurix Therapeutics Ownership | Who Owns Nurix Therapeutics?


OverviewForecastRevenueFinancialsChart

Nurix Therapeutics Ownership Summary


Nurix Therapeutics is owned by 105.38% institutional investors, 1.09% insiders. Blackrock is the largest institutional shareholder, holding 12.42% of NRIX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.14% of its assets in Nurix Therapeutics shares.

NRIX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockNurix Therapeutics105.38%1.09%-6.47%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock6.82M12.42%$142.33M
Blackrock funding, inc. /de8.93M8.11%$138.35M
Redmile group7.73M7.03%$119.86M
Vanguard group5.95M6.26%$112.86M
Vestal point capital, lp6.50M5.91%$100.75M
Deep track capital, lp6.35M5.76%$98.35M
Fmr5.54M5.03%$85.89M
State street5.14M4.67%$79.69M
Morgan stanley4.93M4.48%$76.45M
Baker bros. advisors lp4.66M4.23%$72.21M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Redmile group7.73M7.94%$119.86M
General atlantic4.10M2.96%$63.58M
Vestal point capital, lp6.50M2.82%$100.75M
Commodore capital lp2.27M2.04%$35.26M
Deep track capital, lp6.35M1.61%$98.35M
Foresite capital management v265.00K1.52%$4.11M
Verdad advisers, lp83.42K1.46%$1.29M
Kynam capital management, lp1.19M1.14%$18.52M
Perceptive advisors3.71M1.13%$57.52M
Highvista strategies226.55K0.97%$3.51M

Top Buyers

HolderShares% AssetsChange
Blackrock6.82M0.00%2.24M
Vestal point capital, lp6.50M2.82%1.81M
State street5.14M0.00%1.58M
Vanguard group5.95M0.00%1.46M
Fmr5.54M0.00%1.31M

Top Sellers

HolderShares% AssetsChange
Point72 asset management449.11K0.01%-2.76M
Ra capital management---1.33M
Bain capital life sciences investors---1.13M
General atlantic4.10M2.96%-795.29K
Kynam capital management, lp1.19M1.14%-775.60K

New Positions

HolderShares% AssetsChangeValue
Capital world investors893.33K0.00%893.33K$13.85M
Vanguard fiduciary trust632.23K0.00%632.23K$9.80M
Fisher asset management384.83K0.00%384.83K$5.96M
Raymond james financial353.73K0.00%353.73K$5.20M
D. e. shaw344.20K0.00%344.20K$5.34M

Sold Out

HolderChange
True wealth design-4.00
Ifp advisors-6.00
Nelson, van denburg & campbell wealth management group-9.00
Federated hermes-15.00
Amundi-17.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20261923.23%115,991,7392.27%1050.62%107-19.55%4250.00%
Dec 31, 202539-77.59%15,163,987-82.11%150.16%26-68.67%7-88.14%
Sep 30, 202546-72.12%9,091,319-89.71%100.10%18-80.43%17-59.52%
Jun 30, 2025164-4.09%88,304,1285.07%1051.04%91-3.19%42-17.65%
Mar 31, 2025171-3.93%84,588,6764.29%1010.69%93-11.43%5110.87%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv3.25M3.14%15.55K
State Street® SPDR® S&P® Biotech ETF3.13M3.03%-30.98K
Vanguard US Total Market Shares ETF2.13M2.79%196.50K
iShares Russell 2000 ETF2.38M2.30%20.07K
Fidelity Select Health Care1.69M2.21%90.00K
Xtrackers MSCI World Swap ETF 1C2.14M2.08%-13.47K
US Small-Cap Growth II Equity Comp1.35M1.76%14.21K
Pictet-Biotech P USD1.79M1.73%7.04K
ARK Genomic Revolution ETF1.72M1.67%72.94K
ARK Genomic Revolution1.63M1.57%96.44K

Recent Insider Transactions


DateNameRoleActivityValue
Jun 02, 2026Ring Christine Chief Legal OfficerSell$135.25K
May 05, 2026van Houte Hans Chief Financial OfficerSell$10.00K
May 05, 2026van Houte Hans Chief Financial OfficerSell$223.32K
May 04, 2026Ring Christine Chief Legal OfficerSell$138.21K
May 01, 2026Ring Christine Chief Legal OfficerSell$90.41K

Insider Transactions Trends


DateBuySell
2026 Q2-9
2026 Q1-9
2025 Q4-7
2025 Q3-4
2025 Q2-4

NRIX Ownership FAQ


Who Owns Nurix Therapeutics?

Nurix Therapeutics shareholders are primarily institutional investors at 105.38%, followed by 1.09% insiders and -6.47% retail investors. The average institutional ownership in Nurix Therapeutics's industry, Biotech Stocks , is 35.75%, which Nurix Therapeutics exceeds.

Who owns the most shares of Nurix Therapeutics?

Nurix Therapeutics’s largest shareholders are Blackrock (6.82M shares, 12.42%), Blackrock funding, inc. /de (8.93M shares, 8.11%), and Redmile group (7.73M shares, 7.03%). Together, they hold 27.56% of Nurix Therapeutics’s total shares outstanding.

Does Blackrock own Nurix Therapeutics?

Yes, BlackRock owns 12.42% of Nurix Therapeutics, totaling 6.82M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 142.33M$. In the last quarter, BlackRock increased its holdings by 2.24M shares, a 48.90% change.

Who is Nurix Therapeutics’s biggest shareholder by percentage of total assets invested?

Redmile group is Nurix Therapeutics’s biggest shareholder by percentage of total assets invested, with 7.94% of its assets in 7.73M Nurix Therapeutics shares, valued at 119.86M$.

Who is the top mutual fund holder of Nurix Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Nurix Therapeutics shares, with 3.14% of its total shares outstanding invested in 3.25M Nurix Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools